Lord, Abbett & Co
FOLD

Lord, Abbett & Co’s Amicus Therapeutics FOLD Stock Holding History

Lord, Abbett & Co’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1,440,999
Closed -$17.4M – 787
2018
Q3 		$17.4M Sell
1,440,999
-463
-0% -$6.47K 0.05% 509
2018
Q2 		$22.5M Sell
1,441,462
-65,323
-4% -$987K 0.07% 448
2018
Q1 		$22.7M Buy
+1,506,785
New +$22.9M 0.07% 434
2015
Q4 		– Sell
-2,748,548
Closed -$38.5M – 905
2015
Q3 		$38.5M Buy
2,748,548
+1,741,546
+173% +$27.3M 0.12% 278
2015
Q2 		$14.2M Buy
1,007,002
+317,283
+46% +$3.81M 0.04% 570
2015
Q1 		$7.5M Buy
+689,719
New +$6.08M 0.02% 678

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Lord, Abbett & Co's FOLD Position: Q4 2018 in Review

Lord, Abbett & Co sold out of Amicus Therapeutics (FOLD) in Q4 2018, closing a stake of 1,440,999 shares — an estimated $17.4M sold.

Lord, Abbett & Co first reported a position in FOLD in Q1 2015 and held it in 6 quarters. The position peaked at $38.5M in Q3 2015. 195 funds tracked by Wall St. Rank hold FOLD as of Q4 2018.

  • Lord, Abbett & Co reported no remaining Amicus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Lord, Abbett & Co sold 1,440,999 Amicus Therapeutics shares in Q4 2018, an estimated $17.4M.
  • Lord, Abbett & Co first reported a position in Amicus Therapeutics in Q1 2015 and held it in 6 quarters.
  • Lord, Abbett & Co's Amicus Therapeutics position peaked at $38.5M in Q3 2015.
  • 195 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2018.

Based on Lord, Abbett & Co's 13F filing for Q4 2018, filed 14 Feb 2019.